Hopewell

Hopewell Therapeutics is a preclinical-stage biotechnology company focused on developing next-generation lipid nanoparticle (LNP) delivery systems for genomic medicines. Utilizing its proprietary ttLNP (tissue-targeted LNP) platform, the company aims to deliver nucleic acid payloads, such as mRNA and gene-editing tools, to specific extrahepatic tissues including the lungs and central nervous system. This technology addresses a major bottleneck in the field by enabling precise, organ-specific delivery beyond the liver. Hopewell is advancing a diverse internal pipeline while establishing strategic partnerships to broaden the application of its delivery platform across various therapeutic areas.